| 0 Comments |

799-P: Gender Differences in Diabetes Distress Comparing Dapagliflozin plus Saxagliptin to Glimepiride When Added to Metformin in Poorly Controlled Type 2 Diabetes

MARCIA A. TESTA and DONALD C. SIMONSON, Boston, MA Gender Differences in Diabetes Distress Comparing Dapagliflozin plus Saxagliptin to Glimepiride When Added to Metformin in Poorly Controlled Type 2 Diabetes Author Block: MARCIA A. TESTA, DONALD C. SIMONSON, Boston, MA Distress.
| 0 Comments |

810-P: Patient-reported outcomes in T2D patients inadequately controlled by metformin are more favorable for dapagliflozin plus saxagliptin vs. insulin glargine.

MARCIA A. TESTA, DONALD C. SIMONSON, ELLA EKHOLM, MAXWELL SU, EVA K. JOHNSSON, Boston, MA, Mölndal, Sweden Patient-Reported Outcomes in T2D Patients Inadequately Controlled by Metformin Are More Favorable for Dapagliflozin plus Saxagliptin vs..
| 0 Comments |

1520-P:  Impact of Patient-Centered Factors on Comparative Effectiveness of Initial Therapies in Treatment-Naïve T2D

MARCIA A. TESTA, ALEXANDER TURCHIN, MAXWELL SU, DONALD C. SIMONSON, Boston, MA Impact of Patient-Centered Factors on Comparative Effectiveness of Initial Therapies in Treatment-Naïve T2D Author Block: MARCIA A. TESTA, ALEXANDER TURCHIN, MAXWELL SU,.
| 0 Comments |

941-P: Continuous Glucose Monitoring (CGM) Provides Enhanced Sensitivity Compared with Self-Monitored Blood Glucose (SMBG) for Detecting Hypoglycemia during T2D Clinical Trials.

MARCIA A. TESTA, SERGIO SALDIVAR-SALAZAR, MAXWELL SU, JOHANNA F. HAYES, DONALD C. SIMONSON, Boston, MA, Wellesley Hills, MA Continuous Glucose Monitoring (CGM) Provides Enhanced Sensitivity Compared with Self-Monitored Blood Glucose (SMBG) for Detecting Hypoglycemia.